NTLA Intellia Therapeutics, Inc.
8-K Current Report
Filed: March 2, 2026
Health Care
In Vitro & In Vivo Diagnostic SubstancesIntellia Therapeutics, Inc. (NTLA) 8-K current report filed with SEC EDGAR on March 2, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items3 items
- Item 8.01: Other Events
- Item 1.01: Entry into a Material Definitive Agreement
- Item 7.01: Regulation FD Disclosure
AI Filing Analysis8-K
Item 1.01 · Entry into a Material Definitive Agreement
- • ATM program upsized March 2, 2026 from $750M to ~$1.035B total capacity; $400M in new shares available for sale
- • Already sold ~$635M of shares under prior tranches — significant dilution already absorbed by existing shareholders
Item 7.01 · Regulation FD Disclosure
- • FDA lifted clinical hold on MAGNITUDE Phase 3 trial for ATTR-CM (transthyretin amyloid cardiomyopathy), removing a key regulatory overhang
- • Clinical hold removal allows Intellia to resume/initiate patient enrollment in its pivotal cardiac gene editing trial — critical gating event for NTLA's pipeline
Item 8.01 · Other Events
- • FDA lifted clinical hold on MAGNITUDE Phase 3 trial (ATTR-CM) as of March 2, 2026 — trial enrollment can resume
- • Hold was imposed Oct 29, 2025 after Grade 4 liver transaminase elevation + increased bilirubin in a dosed patient — ~4-month disruption
Other Intellia Therapeutics, Inc. 8-K Filings
Get deeper insights on Intellia Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.